78 results about "Myelin sheath" patented technology

The invention belongs to the technical field of biology, and particularly relates to an SLC44A1 gene and / or SLC44A5 gene knockout animal model as well as a construction method and application thereof. The construction method of the animal model comprises the following steps: deleting exon regions from the fourth exon region to the thirteenth exon region of the SLC44A1 gene and / or the second exon region of the SLC44A5 gene in mouse brain oligodendroglia cells in a high-efficiency manner by utilizing gene editing and a Cre-loxP recombinase system, so as to realize the knockout of a target gene. The animal model constructed by the invention can be used for researching the regulation mechanism of the choline transporters (SLC44A1 and SLC44A5) on myelin sheath formation, deeply knowing the biological functions of the choline transporters (SLC44A1 and SLC44A5), simulating the occurrence and development processes of human related diseases, revealing the pathogenesis of the related diseases, providing a new thought for prevention and treatment of brain myelin sheath dysplasia, and providing a new foundation for the prevention and treatment of brain myelin sheath dysplasia. And an effective drug or a treatment mode aiming at the disease is screened by utilizing a gene knockout animal model, so that a new choice is provided for clinical treatment of the disease.

Method for reversing demyelination in a patient having a demyelinating disorder may include detecting one or more biomarkers for demyelination from the patient, receiving, in an implanted vagus nerve stimulator, a command to apply a remyelinating stimulation to the patient based on a level of the detected one or more biomarkers for demyelination; and applying electrical stimulation to the patient's vagus nerve from the implanted vagus nerve stimulator to reverse demyelination and increase remyelination of the patient's nerves. The electrical stimulation may be adjusted based on the level of the detected one or more biomarkers.

This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular, Bruton tyrosine kinase (“BTK”) inhibitors, for treatment of subjects with myelin oligodendrocyte glycoprotein antibody disease (MOGAD).

To provide a method for generating oligocortical spheroids (OCS) from pluripotent stem cells (PSC).SOLUTION: A method comprises the steps for: a) generating a neurocortical spheroid (NCS) through neurocortical patterning of pluripotent stem cells; b) subjecting the neurocortical spheroid to timed exposure to defined oligodendrocyte lineage growth factors and / or hormones, to promote proliferation, survival and / or expansion of native oligodendrocyte progenitor cell (OPC) populations within the neurocortical spheroid, thereby generating the oligocortical spheroid, wherein the oligocortical spheroid contains oligodendrocyte progenitor cells capable of differentiating into myelinating oligodendrocytes (ODCs) that are capable of myelinating axons.SELECTED DRAWING: Figure 1-1

The invention relates to the technical field of biomedical engineering, and discloses a neural conduction pathway quantitative analysis method and system based on a neural potential waveform. The system comprises: a bioelectric signal acquisition module configured to establish a time sequence characterizing the change of neural current over time; the waveform deep learning module is configured to fit conduction waveforms of the A beta nerve fiber, the A delta nerve fiber and the C-type fiber by using a deep learning algorithm based on the time sequence, and identify a peak point of the conduction waveform of each fiber; the quantitative analysis module is configured to calculate the frequency and intensity function of each fiber conduction signal according to the peak point, and the physiological characteristic parameters comprise the myelination degree, the conduction speed and the sensitivity to anesthetics; and the control module is configured to generate a differential blocking strategy aiming at the A beta nerve fiber, the A delta nerve fiber and the C-type fiber based on the frequency and intensity functions and generate the anesthetic dosage. And specific recognition and differential blocking control of A beta, A delta and C type fiber signals are realized.

A system for treating a subject including a signaling device, a controller, and a stimulator. The signaling device is in communication with the input of the controller and is configured to send a signal to the controller. The stimulator is in communication with the output of the controller and is configured to stimulate an auricular branch of a vagus nerve in an ear of a subject in response to the controller receiving the signal from the signaling device.

To provide a method of treating an inflammatory neurological disease or condition that can result in destruction or degeneration of axons or myelin.SOLUTION: Provided is a combination comprising a) a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof; and b) one or more drugs selected from the group consisting of I) a compound of a particular formula or a pharmaceutically or veterinarily acceptable salt thereof; ii) a sphingosine-1-phosphate receptor inhibitor (S1PR modulator); and iii) a signal transducer and activator of transcription 3 (STAT3) inhibitor.SELECTED DRAWING: None

The present invention belongs to the field of biomedical technology, and particularly relates to the use of dendritic cells in the prevention and / or treatment of demyelinating diseases. The expression level of Talin1 protein in the dendritic cells is reduced or not expressed. Loading the dendritic cells with myelin peptides can safely and effectively alleviate immune inflammation and nerve damage, and thus is expected to develop into a new therapy for the prevention and / or treatment of demyelinating diseases.

The invention relates to the technical field of antibody detection, in particular to a recombinant antigen and application of a transfected living cell immunofluorescence method of the recombinant antigen in anti-myelin oligodendroglia glycoprotein IgG antibody detection. The method comprises the following steps: constructing a myelin sheath oligodendroglia glycoprotein expression plasmid, with an expression plasmid vector being pcdna3.1-target gene-linker-* 3Flag-P2A-EGFP, an amino acid sequence of the expression plasmid gene being as shown in SEQ ID NO: 1, a base sequence of the expression plasmid gene being as shown in SEQ ID NO: 2, carrying out cell transfection to make the expression plasmid enter a target cell, culturing for 16-28 h to obtain a cell immobilized with the expression plasmid, and purifying the cell to obtain the myelin sheath oligodendroglia glycoprotein. The kit can be used for detecting the anti-myelin oligodendroglia glycoprotein IgG antibody by an immunofluorescence staining method. The problems of antigen spatial conformation change, epitope shielding or cell shrinkage of cells are solved, and the detection sensitivity is improved.

A method of generating oligodendroglial progenitor cells and pre-myelinating oligodendrocytes is disclosed. Uses of the cell populations are further described.

The disclosure provides methods for (i) treating multiple sclerosis in patient, (ii) treating a patient having symptoms of multiple sclerosis, (iii) preventing the onset of multiple sclerosis symptoms in patient having multiple sclerosis or predisposed to multiple sclerosis; (iv) promoting or enhancing immunomodulation and remyelination and / or myelin repair in a subject in need thereof; (v) a neuroinflammatory disorder; (vi) Amyotrophic Lateral Sclerosis; or (vii) a demyelinating disease or disorder or a hypomyelinating condition, each method comprising administering a therapeutically effective amount of a bryostatin compound to the patient.

The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.

The invention discloses a magnetic control electric three-layer composite nerve scaffold for nerve regeneration microenvironment stage adaptation and a preparation method thereof. The outer layer of the stent is a PLLA-IAA membrane responding to inflammation microenvironment stimulation, the middle of the stent is an SPIONs-doped piezoelectric layer, and the inner layer of the stent is an Nrg-1-loaded neurotrophic factor sustained release layer. In the initial stage of stent implantation, reactive oxygen species (ROS) stimulates a responsive chain segment to break, and IAA is quickly released to inhibit an inflammatory microenvironment; then, an alternating magnetic field is applied to cause vibration of the SPIONs, formation of an electric signal in the piezoelectric layer is triggered, and a favorable electrophysiological microenvironment is provided for promoting neuronal differentiation and axon regeneration; under the action of environmental degradation, the spinning membrane structure disintegrates slowly and continuously releases the neurotrophic factor Nrg-1 so as to promote myelin sheath formation. The stent innovatively integrates the requirements of three stages of a nerve regeneration microenvironment, and realizes accurate, dynamic and multi-dimensional regulation and control of high-efficiency regeneration.

The application belongs to the technical field of biological drugs, and particularly relates to a preparation method of genetically modified human bone marrow mesenchymal stem cells and application thereof in treating nervous system diseases, in particular, multiple sclerosis. The human bone marrow mesenchymal stem cells are double-modified by brain-derived neurotrophic factor (BDNF) and anti-S1PR5 nanobody, so that the activity of the human bone marrow mesenchymal stem cells is improved, the survival of neurons or oligodendrocytes is promoted, cell apoptosis is inhibited, and myelin regeneration is promoted, and the human bone marrow mesenchymal stem cells can be applied to nervous system diseases, in particular, multiple sclerosis.

The invention provides a composite active dressing for neural restoration and a preparation method and application thereof, and relates to the technical field of medical materials. The composite active dressing comprises a transdermal inner layer and a small extracellular vesicle slow-release outer layer, the transdermal inner layer is of a membrane-shaped structure and comprises a composite active component and a hydrogel matrix material, and the composite active component is selected from one or more of an anti-inflammatory component, a microcirculation improving component, an antioxidant component and a neurotrophic component; the small extracellular vesicle sustained-release outer layer is of a three-dimensional network structure and comprises small extracellular vesicles and a hydrogel matrix material. According to the invention, stable loading and layered deep delivery and release of the small extracellular vesicles are realized, the inflammatory response and microcirculation state of an injured part are improved, proliferation migration and remyelination of Schwann cells can be promoted, and axon regeneration and effective repair of nerve injury can also be promoted.

The invention relates to a dietary therapy formula for repairing ear hearing nerve cells and a preparation method thereof. Components with homology of medicine and food are optimally selected, the salvia miltiorrhiza and the radix puerariae can increase blood flow of inner ears, promote nutrition delivery, inhibit vasospasm of the inner ears and reduce ischemic injury of hair cells, alpha-linolenic acid is provided for a human body by utilizing the flaxseeds and the walnuts and converted into DHA, the DHA directly participates in nerve myelin sheath reconstruction, auditory nerve signal conduction is enhanced, and the health care effect is achieved. Chinese yam and astragalus membranaceus can provide Chinese yam polysaccharide and astragaloside, the mitochondrial function is improved, and cell apoptosis is delayed. The whole component is low in sugar content, is suitable for diabetics, expands the application crowd and non-medicine products, can reduce the psychological burden of eaters taking medicines for a long time, and is beneficial to popularization and application.

The utility model discloses a device convenient for exploring laboratory mouse habits, which comprises a laboratory mouse habit exploring device, a plurality of independent control cabins are arranged in an upper box body of the laboratory mouse habit exploring device at equal angles, and ventilation openings are arranged above the outer arc-shaped side walls of the independent control cabins in a matched mode. A plurality of independent control cabins are arranged on the experimental mouse habit exploration device, humidity controllers and controllable illuminating lamps are arranged in top covers of the independent control cabins at equal angles, temperature control tubes are arranged at the bottoms of the independent control cabins, the independent control cabins are communicated with the central multi-through groove, the experimental mouse habit exploration device is provided with the independent control cabins, and each independent control cabin can achieve simulation of different environments. In this way, the adaptive capacity of the mouse to the environment can be better explored, different external environments can generate different environmental stimuli to the mouse, the external environments can well induce the animal to generate immune response aiming at the myelin sheath component of the central nervous system (CNS), research data can be well compared, and the research result is more accurate. And the data accuracy is higher.

The invention discloses a three-layer nerve conduit based on cell-loaded near-field direct-writing printing and a preparation method and application thereof, and is characterized in that the inner layer of the three-layer nerve conduit is a cell-loaded ALG / GelMA / PEO hydrogel stent, the middle layer is a PVA / GelMA electrostatic spinning membrane, and the outer layer is a fused near-field direct-writing PCL stent; the preparation method comprises the following steps: preparing an ordered fiber membrane PVA / GelMA from a spinning solution through electrostatic spinning, adding the ordered fiber membrane PVA / GelMA into an acetone / glutaraldehyde solution to obtain a PVA / GelMA electrostatic spinning membrane, and printing a direct-writing PCL support on any single surface of the electrostatic spinning membrane through fusion near-field direct-writing. The preparation method comprises the following steps: preparing an ordered cell-loaded hydrogel scaffold from cell-containing bio-ink through cell-loaded near-field direct writing printing, and finally preparing the three-layer nerve conduit, and the three-layer nerve conduit has the advantages of accelerating axon growth, promoting myelin sheath regeneration and improving nerve function recovery.

The invention provides hydrogel for repairing peripheral nerve injury as well as a preparation method and application of the hydrogel, and belongs to the field of biomedical engineering materials. The hydrogel disclosed by the invention is good in biocompatibility, has degradability, contains a double-layer cross-linked network structure, has the wetting characteristic of common hydrogel, and also has the advantages of collagen antigenicity, biodegradability, high biocompatibility, cell adaptability, tissue regeneration promotion and the like. The hydrogel can effectively promote regeneration and remyelination of nerve fibers, can promote gastrocnemius muscle recovery and promote motor function recovery, and has a good application prospect.

The application discloses application of a Histatin-1 polypeptide in preparation of a preparation for promoting sciatic nerve regeneration or repair, and an amino acid sequence of the Histatin-1 polypeptide is shown as SEQ ID NO. 1. The Histatin-1 polypeptide can promote expression of a nerve differentiation index, promote recovery of a functional index after sciatic nerve injury, and promote recovery of a histological index after sciatic nerve injury, for example, recovery of myelin structure and morphology. In addition, in combination with gelatin methacrylate (Gel-MA) as a biological scaffold, slow release of the Histatin-1 polypeptide can be realized, continuous repair support can be provided for a nerve injury site, myelin repair effect is further optimized, a more efficient and more durable solution is provided for treatment of sciatic nerve injury, and the application has a wide application prospect in the field of treatment of myelinated nerve injury.

The present invention relates to a contrast agent composition capable of specifically staining nerve tissue, in which the composition has affinity for myelin and can specifically stain nerve tissue rather than other tissues, has a wavelength in the near-infrared (NIR) region of 700 nm, and can stably emit fluorescence in vivo, and thus can be effectively used for real-time fluorescence imaging to differentiate from other tissues.

The invention provides an application of a nitrogen-containing heterocyclic ring compound in preparation of a medicine for treating peripheral neuropathy. The nitrogen-containing heterocyclic ring compound is SB203580. The peripheral neuropathy refers to diseases or injuries involving a peripheral nervous system, and comprises peripheral nerve trauma, adverse drug reaction and axonal dysfunction caused by one or more pathogenic factors of chemical reagents and diabetes mellitus. Researches show that recovery of a sciatic nerve function index (SFI) after peripheral nerve physical injury (sciatic nerve truncation) of a mouse is remarkably improved, the recovery degree of the signal transduction rate of the injured sciatic nerve is improved, myelin sheath regeneration of the injured sciatic nerve is promoted, and the proportion of abductive myelin sheaths in newly formed myelin sheaths is reduced. The invention provides a new potential medicine for treating the peripheral nerve injury. The structure of the SB203580 is shown in the specification.

Apparatus for the non-invasive in-vivo determination of changes in tissue, e.g. the myelination, of the optic nerve (ON) in a biological subject, said apparatus comprising: a laser source for generating an excitation laser beam; an optical system including a fundus camera operatively associated with the laser source for use in obtaining a fundus image for illuminating the optic nerve (ON) of a subject with the excitation laser beam; a detector (13) operatively associated with the optical system and configured to detect a Raman spectrum from the optic nerve (ON) and / or surrounding cerebral spinal fluid; and a processor provided with a computer program for comparing the detected Raman spectrum to at least one reference spectrum. The reference spectrum may correspond to the myelination of the optic nerve in a normal, healthy subject, for determining the changes in the myelination of the optic nerve of the subject based on the detecting and comparing steps from the Raman spectrum.

The present application relates to a kind of drug composition for preventing and treating recovery stage facial nerve palsy and its application, the composition contains any one or its combination of dehydrating drug, antiviral drug, anti-inflammatory drug, nerve repair drug and / or blood circulation improving drug, traditional Chinese medicine preparation.The drug composition of the present application is combined with radio frequency operation and nerve repair drug and rehabilitation exercise, beneficial to promote trophic nerve, promote myelin and axon repair, with synergistic effect, fast effect, high efficiency, high cure rate, basically no side effect and basically no recurrence rate and the like, significantly improve the treatment prognosis and quality of life of patient.

The application discloses a diagnostic marker detection system of a star-shaped glial cell IL-33 knockout EAE model, relates to the technical field of in vitro diagnosis, and comprises the following steps: constructing direction consistency constraint, four-domain prior weight and anchor point consistency scoring; selecting a minimum panel in four domains of inflammation chemotaxis, T cell subgroups, myelin axons and blood brain barrier, and generating Th17 / Th1 and MMP9 / closure protein ratio and chemotaxis combination; implementing standardized collection, platform alignment and bridge calibration, establishing intra-batch / between-batch quality control and time window limitation; performing learning with monotone constraint and two-stage calibration, and reserving animal-to-human population domain adaptation; and outputting star source index, double-threshold value stratification, longitudinal monitoring and interpretable report, so that cross-platform and cross-batch comparability, direction order preservation, traceability and clinical bridgeability are realized, and robust discrimination and reproducibility are improved.

A system for treating a subject including a signaling device, a controller, and a stimulator. The signaling device is in communication with the input of the controller and is configured to send a signal to the controller. The stimulator is in communication with the output of the controller and is configured to stimulate an auricular branch of a vagus nerve in an ear of a subject in response to the controller receiving the signal from the signaling device.

A method of generating oligodendroglial progenitor cells and pre-myelinating oligodendrocytes is disclosed. Uses of the cell populations are further described.

The application belongs to the technical field of biological medicine, and particularly relates to application of circular RNA as a marker in detection of hand-foot-mouth disease complicated with nerve injury. The application first discovers that hsa_circ_0069335 as a marker is applied in prediction of hand-foot-mouth disease complicated with nerve injury. In an external verification queue, there is no marker in serum samples of patients with nerve injury symptoms, and the area under the ROC curve is 1, which indicates that the marker can be used as a marker of hand-foot-mouth disease complicated with nerve injury, and has excellent specificity and sensitivity. Further, the application discovers that EV71 infection inhibits growth of Schwann cells, myelin formation is damaged, and causes significant damage to the nervous system, which is related to the hsa_circ_0069335 / miR-29b-3p / PMP22 pathway. The discovery may provide a key molecular target for early warning and treatment of severe hand-foot-mouth disease, so as to accelerate the development progress of therapeutic drugs.